Potential risk factors for early acute kidney injury in patients treated with vancomycin

Purpose The acute kidney injury (AKI) onset owing to vancomycin (VCM) is reported that depend on the area under the blood concentration-time curve (AUC) and occur comparison early phase (early AKI). This study aimed to investigate the occurrence of early AKI in patients treated with VCM and new indicators to avoid early AKI. Methods Adult patients who received VCM treatment for more than 4 days and whose trough values measured at least once on or after day 4 and serum creatinine before day 7 from the initiation of VCM administration between August 2021 and September 2022 at the Yamanashi Prefectural Central Hospital were enrolled. Early AKI (defined as AKI occurring within day 7 from VCM administration) and the association between each AUC (0-24, 24-48, 48-72, 0-48, 24-72, 0-72) were investigated. Furthermore, each AUC cut-off value for early AKI was calculated. Result In total, 164 patients were enrolled; early AKI developed in 21 patients and most frequently occurred on day 4. All stratified AUC were associated with early AKI development. The AUC cut-off values were AUC(0-24): 470.8 mu g/mL & sdot;h; AUC(24-48): 473.0 mu g/mL & sdot;h; AUC(48-72): 489.7 mu g/mL & sdot;h; AUC(0-48): 910.2 mu g/mL & sdot;h; AUC(24-72): 1039.2 mu g/mL & sdot;h; and AUC(0-72): 1544.0 mu g/mL & sdot;h. Conclusion The possibility of AKI development owing to the AUC accumulation of VCM was observed (accumulation toxicity). Concentration control through early-phase blood concentration measurements and a transition to AUC(0-48) <910.2 mu g/mL & sdot;h may reduce the early-phase AKI onset.